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Extended-spectrum -lactamases (ESBLs) are active against oxyimino cephalosporins and monobactams.
Twenty-one Klebsiella pneumoniae isolates obtained between 1991 and 1995 at the Princess Alexandra Hospital
in Brisbane, Australia, were subject to amplification and sequencing of the SHV -lactamase-encoding genes.
Thirteen strains were phenotypically ESBL positive. Of these, six strains carried the blaSHV-2a gene and seven
strains carried the blaSHV-12 gene. Eight strains were phenotypically ESBL negative. Of these, seven strains
carried the non-ESBL blaSHV-11 gene and one strain carried the non-ESBL blaSHV-1 gene. There was complete
correspondence between the ESBL phenotype and the presence or absence of an ESBL-encoding gene(s). In
addition, it was determined that of the 13 ESBL-positive strains, at least 4 carried copies of a non-ESBL-
encoding gene in addition to the blaSHV-2a or blaSHV12 gene. A minisequencing-based assay was developed to
discriminate the different SHV classes. This technique, termed “first-nucleotide change,” involves the identi-
fication of the base added to a primer in a single-nucleotide extension reaction. The assay targeted polymor-
phisms at the first bases of codons 238 and 240 and reliably discriminated ESBL-positive strains from
ESBL-negative strains and also distinguished strains carrying blaSHV-2a from strains carrying blaSHV-12. In
addition, this method was used to demonstrate an association between the relative copy numbers of blaSHV
genes in individual strains and the levels of antibiotic resistance.
In recent years the use of oxyimino cephalosporins and
monobactams such as cefotaxime, ceftriaxone, ceftazidime,
and aztreonam has resulted in the selection of -lactamases
that recognize them as substrates. These enzymes are referred
to as extended-spectrum -lactamases (ESBLs), and most of
these are derived from the -lactamases TEM-1 or SHV-1 by
one or more amino acid substitutions (13, 19, 31, 32, 39) and
are encoded on large conjugative plasmids (12, 18, 34).
Klebsiella pneumoniae is a significant cause of hospital-ac-
quired infections. Many K. pneumoniae isolates express ESBLs
of the SHV family. Known SHV variants are listed at http://
www.lahey.org/studies/webt.htm#SHV20. Not all are fully
characterized, but it appears that the majority may be classed
as ESBLs. Almost all SHV-derived ESBLs have a G-to-A
mutation which specifies a glycine-to-serine substitution at
amino acid 238 (numbering according to that of Ambler et al.
[1]), although it has recently been found that substitutions with
alanine or aspartate at that site can also give rise to ESBL
activity (8, 44). An additional G-to-A mutation specifying a
glutamate-to-lysine substitution at amino acid 240 is seen in a
subset of ESBLs. In general, the substitution at position 238
confers a large increase in resistance to cefotaxime and a small
increase in resistance to cetazidime, while the presence of
substitutions at both positions confers a small additional in-
crease in resistance to cefotaxime and a large additional in-
crease in resistance to ceftazidime (4, 7, 31).
Although SHV ESBLs have been documented worldwide,
there are only two published reports of outbreaks in Australian
hospitals. An SHV-5-related ESBL was characterized in a
Western Australian hospital (24) and SHV ESBL-producing K.
pneumoniae was isolated at Princess Alexandra Hospital in
Brisbane, Australia (38). In both cases the SHV ESBLs were
identified and partially characterized on the basis of MICs, the
double-disk synergy test (DDST), and isoelectric focusing
(IEF) and in the former case also by enzyme kinetic analysis.
Accurate identification of ESBLs requires DNA-based
methods. Previously used methods include DNA hybridization
(5, 11, 29), oligotyping (20), restriction fragment length poly-
morphism analysis (27), an immunoassay system (6), PCR-
single stranded conformation polymorphism (2, 25, 26), and
the ligase chain reaction (17). The clinically significant effect
on phenotype conferred by single-nucleotide changes in SHV
ESBLs makes them ideal candidates for the development of a
minisequencing protocol. The minisequencing procedure, or
first-nucleotide change (FNC) method, has previously proved
effective for the detection of polymorphic sites in humans (3, 9,
14, 22, 33). The method interrogates polymorphic sites through
primer annealing immediately upstream of the polymorphic
site followed by determination of the identity of a single base
incorporated. The procedure is performed in microwells and
requires no electrophoresis. It is therefore easy to automate
and, since it produces quantitative results, requires neither skill
nor subjectivity in interpretation.
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In this study we completely characterized by nucleotide se-
quencing the SHV -lactamase-encoding genes found in a
collection of K. pneumoniae isolates from Princess Alexandra
Hospital in Brisbane. These characterized samples were then
used to evaluate the FNC method as a predictor of the resis-
tance phenotype.
MATERIALS AND METHODS
Bacterial strains. Twenty-one strains of K. pneumoniae isolated at Princess
Alexandra Hospital between December 1991 and June 1995 have been previ-
ously described by Schooneveldt and colleagues (38). Thirteen of these were
found to express ESBLs as defined by the DDST (15), and the MICs of cefo-
taxime, ceftazidime, and aztreonam supported this finding.
In addition, Escherichia coli JC411, which carries the blaSHV gene that encodes
the partially characterized ESBL described by Mulgrave and Attwood (24), was
included in some aspects of this study. This strain was supplied by Leigh Mul-
grave at the WA Centre for Pathology and Medical Research, Perth, Western
Australia, Australia.
All strains were cultured in Luria-Bertani broth and stored in cryovials with
12% glycerol at 80°C.
DNA extraction and PCR amplification of blaSHV genes. Plasmid DNA was
extracted from 1.5-ml cultures grown overnight in L-broth using alkaline lysis
(21).
Overlapping regions of the genes were amplified by PCR using primers which
hybridize either to the coding regions (SHV-F, nucleotide position 311 to 328,
TCAGCGAAAAACACCTTG; SHV-R, nucleotide position 782 to 764, TCCC
GCAGATAAATCACCA) (25) or sites adjacent to the coding sequence (BIG-F,
nucleotide position 72 to 52 CGCCGGGTTATTCTTATTTG; BIG-R, nu-
cleotide position 78 to 54 TCTTTCCGATGCCGCCGCCAGTCA. (The 
and  refer to nucleotides upstream of transcription initiation and downstream
of transcription termination, respectively.) PCRs (50 l) were carried out in a
solution containing 1.5 mM MgCl2, 50 mM KCl, 10 mM Tris-HCl (pH 8.3;
Boehringer Mannheim), a 400 M concentration of each deoxynucleoside
triphosphate (Boehringer Mannheim), 20 pmol of each primer (Gibco-Life
Technologies), 100 ng of plasmid DNA template, and 1 U of Taq polymerase
(Boehringer Mannheim). After a 5-min denaturation at 96°C, 35 cycles of tem-
peratures of 96, 55, and 72°C and a final extension step of 72°C for 3 min were
performed. The length of the temperature steps for the 35 cycles were 30 s each
for the coding sequence primers and 1 min each for the primers adjacent to the
coding sequence. Dimethoxyl sulfoxide was added to a final concentration of 5%
when the BIG-F primer was used.
Cloning of blaSHV encoding gene fragments. Amplicons generated from the
clinical isolates A1, F2, J1, J2, and L1 using primers SHV-F and SHV-R were
cloned using the pGEMt plasmid kit (Promega) and JM109 High Efficiency
competent Escherichia coli cells (Promega). Ten to twenty clones were selected
for each isolate, and secondary PCR products were generated from these clones
for sequencing and FNC analysis.
Sequencing. PCR products were purified using Wizard mini-columns (Pro-
mega). Amplicon (50 to 100 ng [10 ng/100 bases]) was sequenced using 3.2 pmol
of the amplification primer. The products were analyzed on an ABI 373A DNA
automated sequencer. Sequence results were aligned using the Clustal W pro-
gram (10), which was accessed through the Australian National Genome Infor-
mation Service at http://www.angis.su.oz.au/.
FNC. FNC is a microtiter plate-based minisequencing (single-nucleotide ex-
tension) assay. A biotinylated primer is hybridized with a PCR-generated target
at a sequence 1 base upstream from a polymorphic site. This complex is captured
by streptavidin-coated microtiter wells. The primer is extended by DNA poly-
merase in the presence of a single fluorescein-labeled dideoxynucleoside triphos-
phate (ddNTP) and unlabeled ddNTPs. Bound fluorescein is detected by en-
zyme-linked immunosorbent assay. The assay is carried out in four wells, each
with a different fluorescein-labeled ddNTP.
A modification of the FNC protocol described by Pecheniuk et al. (33) was
used. Briefly, in a 50-l reaction mixture containing Sequenase buffer (40 mM
Tris HCl [pH 7.51], 20 mM MgCl2, 50 mM NaCl) plus 5% Nonidet P-40 and 5%
Tween 20, 1 pmol of biotinylated primer was bound to 0.6 pmol of amplified
471-bp DNA product by heating at 96°C for 3 min and then rapidly chilling on
dry ice. Three hundred and sixty microliters of a cold solution containing phos-
phate-buffered saline (PBS), 0.1% Tween 20, and 10 mM EDTA was added to
the thawed reaction mix, and 100 l of the resulting mixture was added to each
of four streptavidin-coated microwells. The primer-amplimer complex was al-
lowed to bind to the microplate for 30 min at room temperature.
Unbound material was removed by six washes with PBS–0.1% Tween 20 and
three washes with Sequenase buffer (Amersham Life Science). Extensions were
carried out for 30 min at room temperature in Sequenase buffer using 0.5 U of
Sequenase (Amersham Life Science). Each of the four wells contained a 0.024
M concentration of one of the four fluorescein-labeled ddNTPs plus a 0.3 M
concentration of the remaining three unlabeled ddNTPs. The extension reactions
were carried out in Sequenase buffer, which contained 0.4 mM dithiothreitol, 0.4
mM MnCl2, 0.7 mM Na isocitrate, 0.015% Tween 20, and 0.015% Nonidet.
Incorporation of fluorescein into the captured complex was quantified after
washing six times with PBS–0.1% Tween 20 and incubating for 30 min with 0.03
U of antifluorescein-alkaline phosphatase conjugate (Boehringer Mannheim).
p-Nitrophenyl phosphate (0.1 mg in 100 l of 0.2 M Tris-HCl) was used to detect
the incorporated fluorescein-labeled ddNTP, and the color development was
monitored by absorbance reading at 405 nm with an enzyme-linked immunosor-
bent assay plate reader (Biomek Plate Reader; Beckman Coulter).
Two FNC primers were utilized. MSP-238, 5 biotin-GTTTATCGCCGATA
AGACCGGAGCT, was designed to detect the G-to-A change at position 1 of
codon 238 indicative of ESBLs. MSP-240, 5 biotin-TATCGCCGATAAGACC
GGAGCTAGC, was designed to detect the G-to-A change at position 1 of
codon 240 indicative SHV-12 and similar enzymes, such as SHV-5.
IEF. Cell extracts were focused and bands with -lactamase activity were
visualized with the chromogenic substrate as described by Matthew et al. (23)
with modifications as described by Rasheed et al. (36).
RESULTS
Nucleotide sequencing of the SHV ESBL-encoding genes.
The amplified blaSHV genes from all 21 K. pneumoniae isolates
were sequenced. The results are summarized in Table 1. Genes
encoding SHV variants 1, 2a, 11, and 12 were detected. SHV-1
and SHV-11 are non-ESBLs, and SHV-2a and SHV-12 are
ESBLs. The MICs and DDST results obtained by Schoon-
eveldt et al. (38) and included in Table 1 are consistent with
these DNA sequence data. It is clear that the mutation at
codon 238 confers an increase in MICs over that conferred by
the wild-type precursor, while the mutation in codon 240
causes a considerable further increase in the MICs.
In addition, the blaSHV gene encoding the SHV-5-like en-
zyme described by Mulgrave and Attwood (24) was sequenced.
It was found to encode SHV-12.
Amplicons from strains A1, F2, J1, J2, and L1 yielded se-
quences with clearly visible double GA peaks at position 1 of
codon 238 and/or codon 240. Several clones were constructed
from PCR products derived from these strains, and sequence
analysis revealed that they all possess copies of non-ESBL
SHV-encoding genes in addition to the SHV-2a gene (strains
A1 and F2) or the SHV-12 gene (strains L1, J1, and J2).
Although this sequencing did not encompass codon 35, which
discriminates SHV-2/5 from SHV-2a/12, sequence determina-
tion of the primary PCR products never yielded any sign of
double peaks at that or any other polymorphic sites apart from
at codons 238 and 240, thus indicating that the non-ESBL SHV
blaSHV genes in these strains encode SHV-11.
Limited attempts were made to make use of the clones to
determine the relative copy numbers of the different genes.
Ten clones from strains J1 and J2 were analyzed by FNC at
position 1 of codons 238 and 240. Strain J2 yielded one
SHV-12 sequence, eight SHV-11 sequences, and one failed
assay, while strain J1 yielded two SHV-12 sequences and eight
SHV-11 sequences. This suggests that blaSHV-11 is present at a
higher copy number than blaSHV-12 in these strains. Seven
clones from strain F2 were sequenced across the codon 238
and 240 region, and this yielded four SHV-2a sequences and
three SHV-11 sequences, indicating approximately equal copy
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numbers for the two genes. For strains A1 and L1, two clones
only were sequenced across the codon 238 and 240 region.
Strain A1 yielded one each of SHV-11 and SHV-2a, and strain
L1 yielded one each of SHV-11 and SHV-12, thus indicating
that the relative copy numbers are unlikely to be very different.
FNC results are concordant with -lactamase class and
MICs. A procedure for interrogating the polymorphic nucleo-
tides at the first positions of codons 238 and 240 was devel-
oped. At both positions, the presence of a G is indicative of the
ancestral form while A is indicative of the extended spectrum
of activity. The mutation in codon 238 converts a non-ESBL to
an ESBL, while a second mutation in codon 240 confers very
high activity against the extended-spectrum substrates. Subse-
quent to optimization of the procedure, the reliability of the
method was assessed by carrying out the amplifications and
FNC assays in triplicate.
The results of the FNC assays are shown in Table 2. In order
to fully illustrate the results, the unprocessed absorbance read-
ings (i.e., the absorbance reading using undeveloped color re-
agents as a blank) from one replicate are shown, together with
the mean and standard deviation of the log(A/G) incorpora-
tion using all three replicate experiments. The FNC results are
concordant with the genotyping, DDST, and MIC data. This
indicates it may be feasible to predict MICs from the results of
mutation analyses even when there are complications arising
from the coexistence of different blaSHV variants within indi-
vidual strains. However, this will only be confirmed through
analysis of additional strains expressing a wider variety of SHV
ESBL variants.
IEF. There is a clear difference in MICs between the strains
that have been found to have both blaSHV-12 and blaSHV-11 and
those in which blaSHV-11 was not detected. It may be hypoth-
esized that these groups of strains have different levels of
expression of SHV-12, with expression in the proven heterozy-
gotic strains being lower. To test this, cell extracts were sub-
jected to IEF and then stained for -lactamase activity staining
using nitrocefin. IEF would be expected to resolve SHV-11 and
-2a (pI 7.6) from SHV-12 (pI 8.2). The results were concordant
with the DNA-based assays, and representative strains are
shown in Fig. 1. Strains shown to possess genes encoding SHV-
1/11 and/or SHV-2a yielded bands at pI 7.6, while strains
previously shown to possess genes encoding SHV-12 yielded
bands at pI 8.2 in addition to bands at pI 7.6. Interestingly, all
strains yielded bands at pI 7.6. This indicates that all strains
carrying blaSHV-12 also carry blaSHV-11 and/or blaSHV-1. Con-
sistent with this, the pI 7.6 bands were more intense than the
pI 8.2 bands in strains L1, J1, and J2, which gave genetic
evidence for the coexpression of SHV-11 and SHV-12, while
the relative band intensities were reversed for strains I1, G1,
and H1, in which SHV-11-encoding genes had not been de-
tected. The only exceptions to this were strains K1 and M1,
which yielded bands that were at pI 7.6 (as expected) but
considerably fainter than the bands from other strains, and the
presence of -lactamases with a pI of 5.35 in extracts from
strains B2, C1, K1, and M1. This may be a TEM -lactamase.
Its expression by strains with sensitive (B2, K1, and M1) and
very resistant (C1) phenotypes suggests that it does not con-
tribute to resistance to these antibiotics.
DISCUSSION
This study constitutes the first full characterization of SHV-
ESBLs of Australian origin. Sequence analysis revealed that in
this collection of K. pneumoniae isolates from Princess Alex-
andra Hospital in Brisbane, Queensland, the ESBLs were ex-
clusively of classes 2a and 12, while, with one exception, the
non-ESBL enzymes were SHV-11. These classes are all char-
acterized by a Leu-Gln substitution at amino acid 35 with
TABLE 1. Characteristics of K. pneumoniae isolates in this study
Isolate DDSTa
MIC (g/ml) ofb: Polymorphic codon at position:
Genotype
ATM CAZ CTX 35 238 240
A1  0.5 1 1 CAA (G/A)GC GAG SHV-11/2a
B1  1.0 1 1 CAA AGC GAG SHV-2a
B2  0.03 0.125 0.03 CAA GGC GAA SHV-11
C1  64 64 4 CAA AGC AAG SHV-12
D1  2 4 4 CAA AGC GAG SHV-2a
E1  0.5 1 1 CAA AGC GAG SHV-2a
F1  1 1 1 CAA AGC GAG SHV-2a
F2  0.25 0.5 0.5 CAA AGC GAG SHV-2a
G1  128 128 16 CAA AGC AAG SHV-12
H1  128 128 128 CAA AGC AAG SHV-12
I1  128 128 16 CAA AGC AAG SHV-12
J1  64 32 4 CAA (G/A)GC (G/A)AG SHV-11/12
J2  64 32 2 CAA (G/A)GC (G/A)AG SHV-11/12
J3  0.125 0.5 0.125 CAA GGC GAG SHV-11
J4  0.25 2 0.125 CAA GGC GAG SHV-11
J5  0.06 0.5 0.125 CAA GGC GAG SHV-11
K1  0.06 0.5 0.06 CTA GGC GAA SHV-1
K2  0.03 0.125 0.03 CAA GGC GAA SHV-11
L1  32 32 1 CAA (G/A)GC (G/A)AG SHV-11/12
L2  0.125 0.25 0.25 CAA GGC GAG SHV-11
M1  0.03 0.125 0.03 CAA GGC GAA SHV-11
a These data have been previously reported by Schooneveldt et al. (38).
b Abbreviations: ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime.
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respect to SHV-1 and differ from each other only at position 1
of codons 238 and 240. While the existence of SHV-2a was first
reported in 1991 (35) the existence of SHV-12 has only been
reported more recently in a study of strains of Swiss origin (28).
Although there have been few subsequent reports of these
enzymes, it may be incorrect to conclude that these classes are
rare. In the study carried out by Nuesch-Inderbinen et al. (28)
SHV-2a was found in a high percentage of strains, while in a
recent studies in Eastern Asia they were the most abundant
classes in K. pneumoniae (16, 30, 43). It may be that in certain
parts of the world, SHV-2a and SHV-12 are very common.
Consistent with this, the strain from Western Australia re-
ported to express an SHV-5-like enzyme (24) has now been
shown to possess an SHV-12-encoding gene.
The 21 K. pneuoniae isolates had previously been reported to
possess ESBLs with pI values different from those reported
here (38). It appears that in those experiments, ESBLs with pIs
of 8.2 were not reliably detected. The IEF analyses were re-
peated for this report, and it is now clear that IEF results are
consistent with the genotypes.
The finding that all ESBLs in this study possessed the Leu-
Gln substitution at amino acid 35 is consistent with the model
advanced by Du Bois et al. (7), which states that SHV ESBLs
evolve repeatedly in parallel through mutations at amino acids
238 and 240 and that this can occur in a number of ancestral
non-ESBL enzymes that differ as a result of genetic drift. The
non-ESBL phenotype conferred by SHV-11 shows that the
Leu-Gln substitution has little or no significance with respect
to hydrolysis of expanded-spectrum cephalosporins, and there-
fore its appearance is likely to be due to drift rather than
antibiotic selection.
These data strongly indicate that the ESBLs we have char-
acterized arose from an SHV-11 ancestor. The presence of
SHV-11 in a number of ESBL-negative strains suggests either
that SHV-2a and SHV-12 appeared as result of antibiotic-
mediated selection pressure at the Princess Alexandra Hospi-
tal in Brisbane or that K. pneumoniae strains expressing these
enzymes are ubiquitous in southeast Queensland. The fact that
these strains were isolated in a hospital (38) lends support to
the first alternative.
During the course of this study, it was demonstrated that a
number of strains carried both ESBL and non-ESBL encoding
genes. Elucidation of the precise molecular basis for this phe-
nomenon awaits further analysis, although it is clear that at
least a subset of these strains harbor multiple ESBL-encoding
genes. Indeed, the results of the IEF would indicate that all the
strains harboring ESBL-encoding genes also carry the non-
ESBL-encoding precursor. This result is consistent with the
TABLE 2. Results of FNC assaysd
Isolate Genotypea Base at238a
FNC result forb:
Log(A/G) at position 238c Baseat 240
FNC result for: Log(A/G) at position
240A 238 G 238 A 240 G 240
A1 2a/11 G/A 0.888 0.78 0.065 (0.014) G 0.059 1.362 1.192 (0.141)
B1 2a A 0.726 0.648 0.026 (0.031) G 0.189 2.138 1.011 (0.023)
B2 11 G 0.214 0.527 0.355 (0.026) G 0.101 0.58 0.583 (0.191)
C1 12 A 1.27 0.114 0.902 (0.156) A 1.632 0.102 1.17 (0.086)
D1 2a A 0.789 0.298 0.395 (0.025) G 0.147 1.344 0.962 (0.100)
E1 2a A 0.53 0.62 0.055 (0.013) G 0.134 1.571 0.936 (0.159)
F1 2a A 0.88 0.672 0.124 (0.013) G 0.181 0.848 0.762 (0.154)
F2 2a A 0.934 0.618 0.157 (0.029) G 0.083 1.632 1.034 (0.299)
G1 12 A 1.179 0.187 0.691 (0.111) A 2.252 0.183 0.989 (0.109)
H1 12 A 1.372 0.191 0.780 (0.092) A 1.632 0.132 0.972 (0.122)
I1 12 A 1.568 0.141 0.849 (0.200) A 2.685 0.127 1.201 (0.131)
J1 11/12 G/A 0.48 0.963 0.299 (0.012) G/A 0.688 0.832 0.195 (0.202)
J2 11/12 G/A 0.485 0.741 0.293 (0.162) G/A 0.707 0.565 0.084 (0.010)
J3 11 G 0.061 0.793 0.925 (0.155) G 0.054 0.692 0.852 (0.242)
J4 11 G 0.093 1.172 0.934 (0.167) G 0.073 0.681 0.734 (0.267)
J5 11 G 0.213 0.409 0.395 (0.163) G 0.12 0.475 0.520 (0.080)
K1 1 G 0.045 0.329 0.431 (0.314) G 0.117 0.43 0.327 (0.175)
K2 11 G 0.162 0.919 0.692 (0.059) G 0.133 0.691 0.657 (0.057)
L1 11/12 G/A 0.856 0.702 0.062 (0.044) G/A 1.328 0.468 0.489 (0.068)
L2 11 G 0.061 1.001 1.033 (0.195) G 0.054 0.61 0.821 (0.214)
M1 11 G 0.049 0.751 0.488 (0.543) G 0.112 1.032 0.804 (0.129)
a Genotypes as determined by PCR, cloning, and sequencing.
b The unprocessed absorbance readings from one replicate of the FNC assays.
c The mean of three replicates with the standard deviations in parentheses. The ratios were calculated from unprocessed absorbance readings.
d The signals for the incorporation of the other two bases were also determined (data not shown). These absorbance readings did not exceed 0.23 and in the great
majority of cases were 0.1.
FIG. 1. IEF of extracts from four representative K. pneumoniae
strains. The strain designations are shown above each lane. pIs are
shown at left.
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observations of Xiang et al. (42), who reported that very high
levels of ESBL-mediated resistance are due to the gene am-
plification on low-copy-number plasmids. The failure to detect
non-ESBL-encoding clones derived from all amplimers from
ESBL-positive strains may be explained by the variation in the
relative copy numbers of the ESBL- and non-ESBL-encoding
genes and the limited number of amplimer-derived clones that
were subject to sequence analysis.
It is currently unknown whether the genes encoding non-
ESBLs in ESBL-positive strains are located on the chromo-
some or on plasmids. All genetic analyses in the present study
were carried out using alkaline lysis plasmid preparations
which would be unlikely to contain significant chromosomal
DNA. However, there are reports of chromosomally located
blaSHV-1 genes in K. pneumoniae (37), and it now seems as if
the great majority of K. pneumoniae isolates carry the blaSHV-1
gene (G. S. Babini and D. M. Livermore, Letter, Antimicrob.
Agents Chemother. 44:2230, 2000). We cannot rule out the
possibility that the plasmid preparations were contaminated
with small quantities of chromosomal DNA and that some of
the genes we have detected are chromosomally located.
It is of interest that in the case of the isolates carrying
blaSHV-2a, there were a significant (up to eightfold) range of
MICs without any corresponding differences in copy numbers
as evidenced by the FNC results. This may be due to, e.g.,
differences in the porin content of the isolates. This has been
demonstrated to modulate resistance levels (41).
In this study we demonstrated the potential of the FNC
minisequencing technique in diagnostic microbiology. FNC
and similar methods have previously been used in human ge-
netics (4, 9, 14, 22), but this approach has not been previously
applied to the genotyping of bacteria. ESBL detection was
considered a suitable application for FNC analysis because a
very small number of known polymorphisms result in pheno-
typic changes of clinical significance. Since non-DNA-based
methods for ESBL detection are relatively easy and inexpen-
sive, it is possible that DNA-based methods will not prove to be
competitive in the clinical laboratory environment. Neverthe-
less, the FNC method is carried out in microplates, is quanti-
tative, and does not involve electrophoresis. It is therefore
suitable for automation and may prove effective in situations
requiring the rapid screening of large numbers of samples.
Additionally, the reaction could be incorporated into a DNA
SNP array format as described by Tonisson et al. (40).
We have demonstrated the potential of the FNC method to
accommodate the presence of multiple blaSHV variants within
single strains and variations in the relative copy numbers of
these different variants. Of most significance is the correlation
of MICs, gene identities, and relative copy numbers. It is re-
markable that with these strains, the blaSHV-11 genes can serve
as intracellular standards for measuring the copy number of
ESBL-encoding genes, thus providing a simple strategy for
predicting resistance using a DNA-based assay.
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